Approaching Regulatory Approval of Cardiovascular Regenerative Therapy
- 16 February 2018
- journal article
- editorial
- Published by Ovid Technologies (Wolters Kluwer Health) in Circulation Research
- Vol. 122 (4), 552-554
- https://doi.org/10.1161/circresaha.117.312520
Abstract
After 25 years of research and well over a decade after the first randomized blinded clinical trials suggested benefit of stem cell therapy on cardiac performance, the field seems no closer to clinical approval of a product, and skepticism exists about the viability of the idea that myocardial regeneration can be effected. What has kept the field from crossing the finish line of clinical approval and is the goal in site?Keywords
This publication has 14 references indexed in Scilit:
- The RENEW TrialJACC: Cardiovascular Interventions, 2016
- Innovation in the pharmaceutical industry: New estimates of R&D costsJournal of Health Economics, 2016
- Executive Summary: Heart Disease and Stroke Statistics—2015 UpdateJournal of the American College of Cardiology, 2015
- Heart Disease and Stroke Statistics—2015 UpdateJournal of the American College of Cardiology, 2015
- Angiotensin–Neprilysin Inhibition versus Enalapril in Heart FailureThe New England Journal of Medicine, 2014
- Thrombus Aspiration during ST-Segment Elevation Myocardial InfarctionThe New England Journal of Medicine, 2013
- Adult Bone Marrow Cell Therapy Improves Survival and Induces Long-Term Improvement in Cardiac ParametersJournal of the American College of Cardiology, 2012
- Intramyocardial, Autologous CD34+ Cell Therapy for Refractory AnginaCirculation Research, 2011
- Running a tightrope: Regulatory challenges in the development of antiretroviralsAntiviral Research, 2010
- Intramyocardial Transplantation of Autologous CD34 + Stem Cells for Intractable AnginaJournal of the American College of Cardiology, 2007